TOKYO, June 7 (Bernama-BUSINESS WIRE) — Otsuka Chemical Co., Ltd. (Head office: Chuo-Ku, Osaka; President & Representative Director: Takeharu Harashima; hereinafter “Otsuka Chemical”) announces that it has succeeded part of the Cefixime business from Astellas Pharma, Inc. (Head Office: Chuo-Ku, Tokyo; President & CEO: Kenji Yasukawa, Ph.D.; hereinafter “Astellas Pharma”).
Through this agreement, Otsuka Chemical acquires the business of Cefixime from Astellas Pharma to supply the API (Active Pharmaceutical Ingredient) to overseas licensees along with assets such as contracts belonging to the licensing business and the trademark. This means our company’s entry into the API business, resulting in strengthening the integrated antibiotic-related business from intermediates to API.